SCHEMBL15664366

SCHEMBL15664366

FC(F)(F)c1cccc(CCN2CCN(c3nc(-c4cc(Cl)ccn4)ns3)CC2)c1.Fc1ccc(CCN2CCN(c3nc(-c4cc(Cl)ccn4)ns3)CC2)cc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 7/20 0.42
SIGMAR1 Q99720 1/20 0.41
CYP3A4 P08684 6/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
NFKB1 P19838 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C19 P33261 1/20 0.40
THPO P40225 1/20 0.40
MTOR P42345 1/20 0.40
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
ABCC1 P33527 8/20 0.39
HTR2C P28335 1/20 0.38
CNR2 P34972 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14488466 0.95 HTR1A (0.46) HTR1ASIGMAR1CYP3A4ALDH1A1CYP1A2
SCHEMBL14488276 0.91 ABCC1 (0.45) HTR1ACYP3A4ABCC1
SCHEMBL14488210 0.84 HTR1A (0.48) HTR1ASIGMAR1CYP3A4ALDH1A1CYP1A2
SCHEMBL14486417 0.83 HTR1A (0.42) HTR1ASIGMAR1HTR2CDRD2HTR2A
SCHEMBL14486076 0.82 SIGMAR1 (0.49) HTR1ASIGMAR1TDP1DRD2HTR2A
SCHEMBL14486854 0.82 HTR1A (0.48) HTR1ASIGMAR1CYP3A4ALDH1A1CYP1A2
SCHEMBL14486750 0.81 SMYD2 (0.42) HTR1ASIGMAR1CYP3A4TDP1DRD2
SCHEMBL14486543 0.81 HTR1A (0.48) HTR1ASIGMAR1CYP3A4ALDH1A1CYP1A2
SCHEMBL14488214 0.80 HTR1A (0.44) HTR1ASIGMAR1CYP3A4ALDH1A1CYP1A2
SCHEMBL14488568 0.79 FAAH (0.48) HTR1ASIGMAR1CYP3A4ABCC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140128404-A1 1, 2, 4-Thiadiazol-5-Ylpiperazine derivatives useful in the treatment of neurodegenerative diseases REMYND NV (BE) 2014-05-08 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140128404-A1 1, 2, 4-Thiadiazol-5-Ylpiperazine derivatives useful in the treatment of neurodegenerative diseases MAPT, PSEN1, PSEN2 HTR1A 1628/4885SIGMAR1 2467/4885CYP3A4 3554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.